Ospemifene
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ospemifene |
| DrugBank ID | DB04938 |
| Brand Names (EU) | Senshio |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.98% |
Approved Indication (EMA)
Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | leprosy | 98.98% | DL |
| 2 | pulmonary hypertension | 98.95% | DL |
| 3 | kyphoscoliotic heart disease | 98.78% | DL |
| 4 | migraine with or without aura, susceptibility to | 98.69% | DL |
| 5 | migraine disorder | 98.53% | DL |
| 6 | migraine with brainstem aura | 98.27% | DL |
| 7 | nephrogenic syndrome of inappropriate antidiuresis | 97.99% | DL |
| 8 | rheumatoid arthritis | 97.43% | DL |
| 9 | atrophoderma vermiculata | 97.21% | DL |
| 10 | ulerythema ophryogenesis | 96.78% | DL |
| 11 | brachydactyly-syndactyly syndrome | 96.56% | DL |
| 12 | coronary artery disease | 96.46% | DL |
| 13 | pulmonary hypertension, primary, autosomal recessive | 96.36% | DL |
| 14 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 96.21% | DL |
| 15 | hypertrichosis (disease) | 96.09% | DL |
| 16 | persistent Mullerian duct syndrome | 95.80% | DL |
| 17 | anomalous left coronary artery from the pulmonary artery | 95.78% | DL |
| 18 | obsolete patella aplasia, coxa vara, and tarsal synostosis | 95.60% | DL |
| 19 | Ambras type hypertrichosis universalis congenita | 95.52% | DL |
| 20 | malformation syndrome with odontal and/or periodontal component | 95.49% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.